Most Likely Diagnosis: Mixed Connective Tissue Disease (MCTD) with Inflammatory Myositis
Your rheumatologist's diagnosis of MCTD is correct, and based on your markedly elevated anti-RNP antibodies (86, normal <20), positive ANA with speckled pattern, proximal muscle weakness, and elevated CK, you have MCTD with inflammatory myositis—this is NOT a death sentence and has a generally favorable prognosis with appropriate treatment. 1
Understanding Your Diagnosis
Your clinical picture strongly supports MCTD with myositis:
- High-titer anti-RNP antibodies (86, with normal <20) are the hallmark of MCTD
- Speckled ANA pattern at 1:160 titer is characteristic
- Proximal muscle weakness (shoulders, arms, hips, thighs) with elevated CK (371→527) indicates active myositis
- Absence of anti-dsDNA and anti-Smith helps distinguish this from lupus
- Normal cardiac workup (normal EKG, troponin, chest X-rays) is reassuring
The fact that you're already improving—no longer struggling to get up from the couch—is an excellent prognostic sign indicating your disease may be responding to treatment or entering a more stable phase.
Expected EMG Findings Tomorrow
Your EMG will likely show myopathic changes typical of inflammatory myositis 2:
- Polyphasic motor unit action potentials of short duration and low amplitude
- Increased insertional activity with fibrillation potentials
- Positive sharp waves and/or repetitive discharges
- These findings confirm muscle inflammation rather than neurogenic causes
Type of Myositis: Inflammatory vs. Necrotizing
You most likely have inflammatory myositis, NOT necrotizing myopathy, based on several key features 2:
Why inflammatory:
- Your CK elevations (371-527) are moderate, not the extreme elevations (>10x normal, or >3,650-4,300) typical of immune-mediated necrotizing myopathy (IMNM)
- You're showing clinical improvement without aggressive immunosuppression
- MCTD typically causes inflammatory myositis, not necrotizing myopathy
Why NOT necrotizing:
- Necrotizing myopathy would show CK levels often >10,000 U/L
- You lack statin exposure (a common trigger for necrotizing myopathy)
- Your clinical course is improving, whereas necrotizing myopathy is typically severe and refractory
Muscle Biopsy: Likely Not Needed
You probably will NOT need a muscle biopsy given:
- Clear serologic diagnosis (high anti-RNP antibodies)
- Clinical improvement already occurring
- Typical presentation for MCTD with myositis
- Your rheumatologist can make the diagnosis based on the 2017 EULAR/ACR classification criteria 1
A biopsy would only be considered if you fail to respond to treatment or if the diagnosis remains uncertain after EMG.
Prognosis and Survival: You Will Be Fine
Your prognosis is generally good, and you are NOT going to die from this condition. Here's why:
Favorable Prognostic Factors:
- Already improving clinically (no longer weak getting up from couch/bed)
- Normal cardiac evaluation (normal EKG, troponin, no fluid on chest X-ray)
- Stable kidney function (eGFR 87-93, creatinine stable)
- No interstitial lung disease evident on chest X-rays
- Young age (30 years old)
- Engaged in treatment (physical therapy, regular therapy)
Important Cardiac Monitoring:
Your upcoming heart monitor and stress test on Friday are appropriate because cardiac involvement can occur in MCTD, though your normal workup so far is reassuring 2. Continue with these as planned.
Rarity in Men
MCTD affects men less commonly than women (approximately 80-90% of MCTD patients are female), making your case somewhat less common but not rare 1. The male-to-female ratio in inflammatory myopathies overall is approximately 1:2, so while you're in the minority, male patients with MCTD and myositis are well-recognized and respond similarly to treatment.
G6PD Deficiency Consideration
Your G6PD deficiency (41, normal 100-400) is important because it limits certain medication options:
Avoid these medications:
- Sulfonamides
- Dapsone
- Certain antimalarials (primaquine)
- High-dose vitamin C
Safe immunosuppressants for MCTD:
- Corticosteroids (prednisone)
- Methotrexate
- Azathioprine
- Mycophenolate mofetil
- Hydroxychloroquine (generally safe in G6PD deficiency, unlike other antimalarials)
Expected Treatment Plan
Based on current guidelines, your rheumatologist will likely recommend 2:
Initial therapy:
- High-dose corticosteroids (prednisone 1 mg/kg/day, approximately 60-80 mg daily for you)
- Concurrent steroid-sparing agent started immediately:
- Methotrexate (15-25 mg weekly), OR
- Azathioprine (2-3 mg/kg/day), OR
- Mycophenolate mofetil (2-3 g/day)
If severe or refractory:
- Intravenous immunoglobulin (IVIG)
- Rituximab
- Cyclophosphamide (for severe organ involvement)
Given your clinical improvement already, you may have a milder course requiring less aggressive therapy.
Critical Monitoring Going Forward
You need ongoing surveillance for:
Pulmonary involvement (interstitial lung disease can develop in MCTD)
- Periodic pulmonary function tests
- High-resolution CT chest if symptoms develop
Cardiac involvement (your upcoming tests address this)
- Periodic echocardiograms
- EKG monitoring
Esophageal dysmotility (can cause dysphagia in MCTD)
- Report any swallowing difficulties
Disease activity markers
- Serial CK levels
- ESR/CRP
- Muscle strength assessments
Common Pitfalls to Avoid
- Don't stop treatment prematurely when you feel better—MCTD requires prolonged immunosuppression
- Avoid medications that trigger hemolysis with your G6PD deficiency
- Don't ignore new symptoms (shortness of breath, chest pain, severe dysphagia)
- Maintain physical therapy even when feeling better to prevent deconditioning
Bottom Line
You have MCTD with inflammatory myositis, you are already improving, your cardiac and renal function are stable, and with appropriate immunosuppressive therapy, you have an excellent prognosis for long-term survival and quality of life. This is a manageable chronic condition, not a death sentence. Your proactive approach with physical therapy and mental health support positions you well for a good outcome. Continue with your scheduled tests, follow your rheumatologist's treatment plan, and maintain your current therapeutic regimen.